Navigation Links
Neurocrine Biosciences Presents Elagolix Data
Date:6/16/2009

ogram include, but are not limited to, risk that the Company's elagolix Phase II clinical trials will fail to demonstrate that elagolix is safe and effective; risk that elagolix will not proceed to later stage clinical trials; risk associated with the Company's dependence on corporate collaborators for development, commercial manufacturing and marketing and sales activities. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2008 and report on Form 10-Q for the quarter ended March 31, 2009. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
2. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Reports First Quarter 2008 Results
5. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
6. SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production
7. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
8. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
9. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
10. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
11. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technology used to develop and produce enzymes ... biopharmaceuticals, and industrial enzymes industries, today announced the ... Bioenergy for commercial scale production of Abengoa,s proprietary ... developed under Abengoa,s license agreement with Dyadic. ...
(Date:10/1/2014)... NEW YORK , October 1, 2014 ... and service provider for the medical industries, announced today the expansion ... New York City . genae Americas was incorporated ... is strategically centered in one of the highest concentrations of medical ... Philippe Kassab , President at genae Americas. "The expansion of genae ...
(Date:10/1/2014)... Oct. 1, 2014  Varian Medical Systems (NYSE: ... results for the fourth quarter of fiscal year 2014 ... 22, 2014.  The news release will be followed by ... p.m. PT.  The news release and a link to ... company website at: www.varian.com/investor .  To access the ...
Breaking Medicine Technology:Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3genae Opens Offices in New York City 2Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
(Date:10/1/2014)... 2014 Beverly Hills licensed Clinical Psychologist ... celebrating 20 years of private practice in her Beverly ... to achieve greater joy and fulfillment in their relationships. ... signs and suggestions for anyone who suspects they are ... “Believe it or not, it’s not always easy to ...
(Date:10/1/2014)... 01, 2014 Diet Doc understands that many ... lose weight and their dieting attempts could be easily sabotaged ... hormone diet treatments into their programs as a ... see fast and effective weight loss results, it also allows ... habits to maintain their weight for the future. , Earlier ...
(Date:10/1/2014)... Raleigh, NC (PRWEB) October 01, 2014 ... combination of three drugs that target immune system proteins ... Surviving Mesothelioma has just posted details of the new ... the story now. , Researchers in the UWA ... TGF-ß, and anti-CTLA-4 drugs to mice with mesothelioma with ...
(Date:10/1/2014)... California (PRWEB) October 01, 2014 ... to benefit a very special cause. The campaign—“Buy ... support for Paws for Veterans, a nonprofit organization ... while also rescuing shelter dogs that would otherwise ... of featured products will support monthly donations of ...
Breaking Medicine News(10 mins):Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2
... foundation set up by the Bill and Melinda Gates ... HIV-AIDS ambassador in India. // The officials said that ... the disease in the country.,The official release said that ... disease is a welcomed step in reducing the stigma ...
... is a country that wakes up to new things and accepts ... catching up.// Here doctors maintain there records in papers and are ... a job to document doctors’ patient records., ,In contrast, in ... maintained in the electronic format. ,MT industry in the US is ...
... benefit of doctors, hospitals and patients in mind a team ... will help doctors to prescribe prescriptions// to patients, based on ... Nicholson at Imperial College London led the study and made ... naturally by the body, in a group of rats before ...
... by the scientists at St. Jude Children’s Research Hospital ... suppressor gene resulted in aggressive leukemias.// Researchers have used ... and drug resistant nature of the acute lymphoblastic leukemia ... a mutation called Bcr-Abl and the loss of both ...
... of the money spent on buying over-the-counter cough medicines is ... so-called cough remedies may be ineffective. // It is stated ... year to these nonprescription cough medicines. ,There are many ... active ingredients in a limited number of strengths and combinations. ...
... accused China of removing organs from executed prisoners and ... their families//. ,There is increasing evidence, which ... for human transplantation purposes in an illegal way, according ... number of organs harvested from prisoners is currently unknown. ...
Cached Medicine News:Health News:Rising in career top charts is Medical transcription 2Health News:Mouse Models To Determine The Cause Of Aggressive Leukemia 2Health News:Mouse Models To Determine The Cause Of Aggressive Leukemia 3Health News:Executed Prisoner Organs For Sale In China: BTS Concerned 2
Improve your refractive outcome, with AXIS II precision biometry A-scan. Biometry clinically proven as accurate as partial coherence interferometry while not limited by dense media....
... with graphic display and IOL power ... combination units include firmware module with ... II formulas. Audible tones increase in ... visual axis. Constant tone when alignment ...
... ISYSTEM-ABD ("I-cubed") is an exceptionally high ... analog oscilloscope (static deflection) display. This ... than low cost video monitors. Vitreous ... inflammatory cells, as well as tumor ...
... a sensitive B-scan system which quickly identifies ocular ... both eyes differ by more than 0.3 mm, ... suspected. The B5500 enables quick and easy identification ... bath or inserting shells under the lids. The ...
Medicine Products: